Update From AACR-NCI-EORTC: PYNNACLE phase 2 study

32 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Drs Alison Schram and Elena Garralda share expert insights on the PYNNACLE Phase 2 initial analysis at AACR–NCI–EORTC 2025.

The PYNNACLE phase 2 study evaluates rezatapopt, a first-in-class p53 reactivator, as a treatment for TP53 Y220C–mutant advanced solid tumours.

In this video, the experts discuss:

• TP53 Y220C mutation and the rationale for mutant p53 reactivation
• Study overview and practice implications, spotlighting ovarian cancer
• Testing strategies for early and accurate patient identification

*Rezatapopt is an investigational agent which is not approved by a regulatory agency

Visit the COR2ED website to learn more and download the accompanying slides and poster for more information here: https://cor2ed.com/n-connect/programmes/update-from-aacr-nci-eortc-2025/


Clinical takeaways:

• Reactivating p53 Y220C protein is a promising therapeutic strategy for patients with solid tumours specifically ovarian cancer, with TP53 Y220C mutations, where effective targeted therapies and biomarkers are limited.

• Rezatapopt is a first-in-class investigational p53 reactivator that selectively binds to the mutated p53 Y220C protein, stabilising its structure to restore wild-type tumour suppressor activity.

• Rezatapopt demonstrates rapid, durable and broad antitumour activity in TP53 Y220C–mutant solid tumours, with a particularly strong signal in ovarian cancer, and a generally manageable safety profile.

• Looking ahead, it will be important to prioritise early and accurate identification through up-front comprehensive genomic profiling using NGS with TP53 gene coverage. Tissue is preferred; when tissue is limited, selected ctDNA assays capable of excluding CHIP may be used.


This programme has been sponsored by PMV Pharma

Published October 2025
Categoria
Oncology
Commenta per primo questo video.

Prossimo